[HTML][HTML] Association of inherited mutations in DNA repair genes with localized prostate cancer
Background Identification of germline mutations in DNA repair genes has significant
implications for the personalized treatment of individuals with prostate cancer (PrCa) …
implications for the personalized treatment of individuals with prostate cancer (PrCa) …
Genetic testing in prostate cancer
AO Sokolova, HH Cheng - Current oncology reports, 2020 - Springer
Abstract Purpose of Review This review summarizes recent advances in prostate cancer
(PCa) genetics. Recent Findings Upwards of 20% of metastatic castration-resistant prostate …
(PCa) genetics. Recent Findings Upwards of 20% of metastatic castration-resistant prostate …
[HTML][HTML] DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision …
Prostate cancer (PCa) has a distinct molecular signature, including characteristic
chromosomal translocations, gene deletions and defective DNA damage repair …
chromosomal translocations, gene deletions and defective DNA damage repair …
Inherited mutations in Chinese men with prostate cancer
Background: Although China accounts for 7.8% of worldwide new prostate cancer (PCa)
cases and 14.5% of new deaths according to GLOBOCAN 2020, the risk of PCa associated …
cases and 14.5% of new deaths according to GLOBOCAN 2020, the risk of PCa associated …
[HTML][HTML] HnRNP-L-regulated circCSPP1/miR-520h/EGR1 axis modulates autophagy and promotes progression in prostate cancer
The circRNAs, a new subclass of non-coding RNAs that are catalyzed by RNA-binding
proteins (RBPs), have been reported to be associated with the progression of multiple types …
proteins (RBPs), have been reported to be associated with the progression of multiple types …
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence
Poly (ADP-ribose) polymerase inhibitors (PARPi) are the first clinically approved agents
designed to exploit synthetic lethality. Based on the recent approvals, PARPi became …
designed to exploit synthetic lethality. Based on the recent approvals, PARPi became …
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial
N Reizine, EE Vokes, P Liu… - Therapeutic …, 2020 - journals.sagepub.com
Background: Many cancer patients who receive chemotherapy experience adverse drug
effects. Pharmacogenomics (PGx) has promise to personalize chemotherapy drug dosing to …
effects. Pharmacogenomics (PGx) has promise to personalize chemotherapy drug dosing to …
[HTML][HTML] Orexins/hypocretins and cancer: a neuropeptide as emerging target
C Alain, N Pascal, G Valérie, V Thierry - Molecules, 2021 - mdpi.com
Over 20 years ago, orexin neuropeptides (Orexin-A/hypocretin-1 and Orexin-B/hypocretins-
2) produced from the same precursor in hypothalamus were identified. These two …
2) produced from the same precursor in hypothalamus were identified. These two …
Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection
A LeVee, CY Lin, E Posadas, R Figlin… - OncoTargets and …, 2021 - Taylor & Francis
Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease
with a median survival of 36 months. With the advent of genetic sequencing to identify …
with a median survival of 36 months. With the advent of genetic sequencing to identify …
[HTML][HTML] Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and …
J Cao, WC Chan, MSS Chow - … Journal of Oncology, 2022 - spandidos-publications.com
Prostate cancer mortality is ranked second among all cancer mortalities in men worldwide.
There is a great need for a method of efficient drug screening for precision therapy …
There is a great need for a method of efficient drug screening for precision therapy …